Protein kinase C ε translocation and phosphorylation by cis- diamminedichloroplatinum(II) (CDDP): Potential role in CDDP-mediated cytotoxicity

Cell Growth and Differentiation

Volumn 9, Issue 4, 1998, Pages 345-353

  Ohmori, Tohru ^a,d   Arteaga, Carlos L ^a,b,c,e  

^a Department of Medicine ^*  (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SHOWA UNIVERSITY   (Japan)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; PACLITAXEL; PROTEIN KINASE C;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TRANSPORT;

EID: 0031843617     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (Washington DC), 258: 607-614, 1992.
2. Olivier, A. R., Kiley, S. C., Pears, C., Schaap, D., Jaken, S., and Parker, P. J. Protein kinase C-δ and -∈: a functional appraisal. Biochem. Soc. Trans., 20: 603-607, 1992.
3. Goodnight, J., Mischak, H., and Mushinski, J. F. Selective involvement of protein kinase C isozymes in differentiation and neoplastic transformation. Adv. Cancer Res., 64: 159-209, 1994.
4. Johannes, F. J., Prestlle, J., Eis, S., and Pfizenmaier, K. PKC μ is a novel, atypical member of the protein kinase C family. J. Biol. Chem., 269: 6140-6148, 1994.
5. Takenaka, I., Morin, F., Seizinger, B. R., and Kley, N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem., 270; 5405-5411, 1995.
6. May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatsha, K. A., and Davidson, N. E. lnterleukin-3 and bryostatin-1 mediate hyperphosphorylation of Bcl2 α in association with suppression of apoptosis. J. Biol. Chem., 269: 26865-26870, 1994.
7. Basu, A., and Cline, J. S. Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int. J. Cancer, 63: 597-603, 1995.
8. Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H., and Hofmann, J. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer, 57: 104-110, 1994.
9. Loether, P. J., and Einhorn, L. H. Cisplatin. Ann. Intern. Med., 100: 704-713, 1984.
10. Reed, E., Dabholker, M., and Chabner, B. A. Platinum analogues. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, pp. 357-378. New York: Lippincott-Raven, 1996.
11. Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Uberall, F., and Grunicke, H. H. Enhancement of the antiproliferative effect of cis-diammine dichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer, 42: 382-388, 1988.
12. Basu, A., Teicher, B. A., and Lazo, J. S. Involvement of protein kinase C in phorbol ester-induced sensitization of HELA cells to cis-diamminedichloroplatinum(II). J. Biol. Chem., 265: 8451-8457, 1990.
13. Isonishi, S., Hom, D. K., Eastman, A., and Howell, S. B. Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line. Br. J. Cancer, 69: 217-221, 1994.
14. Christen, R. D., Hom, D. K., Porter, D. C., Andrews, P. A., Macleod, C. L., Hafstrom, L., and Howell, S. B. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest., 86; 1632-1640, 1990.
15. Isonishi, S., Andrews, P. A., and Howell, S. B. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-α. J. Clin. Invest., 90: 1436-1442, 1992.
16. c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between and oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-3765, 1994.
17. Hofmann, J., Uberall, F., Posch, L., Maly, K., Herrmann, D. B. J., and Grunicke, H. Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids, 24: 312-317, 1989.
18. Nishio, K., Sugimoto, Y., Fujiwara, Y., Ohmori, T., Morikage, T., Takeda, Y., Ohata, M., and Saijo, N. Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II). J. Clin. Invest., 89: 1622-1628, 1992.
19. Disatnik, M-H., Winner, A. R., Mochly-Rosen, D., and Arteaga, C. L. Distinct responses of protein kinase C isozymes to c-erbB-2 activation in SKBR-3 human breast carcinoma cells. Cell Growth Differ., 5: 873-880, 1994.
20. Koide, H., Ogita, K., Kikkawa, U., and Nishizuka, Y. Isolation and characterization of the ∈ subspecies of protein kinase C from rat brain. Proc. Natl. Acad. Sci. USA, 89: 1149-1153, 1992.
21. Ohno, S., Mizuno, K., Adachi, Y., Hata, A., Akimoto, S., Osada, S., Hirai, S., and Suzuki, K. Activation of novel protein kinases Cδ and C∈ upon mitogenic stimulation of quiescent rat 3Y1 fibroblasts. J. Biol. Chem., 269: 17495-17501, 1994.
22. Olivier, A. R., and Parker, P. J. Bombesin, platelet-derived growth factor, and diacylglycerol induce selective membrane association and down-regulation of protein kinase C isotypes in Swiss 3T3 cells. J. Biol. Chem., 269; 2758-2763, 1994.
23. Ormerod, M. G., O'Neill, C. F., Robertson, D., and Harrap, K. R. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp. Cell Res., 211: 231-237, 1994.
24. Shinomiya, N., Shinomiya, M., Wakiyama, H., Katsura, Y., and Rokutanda, M. Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death. Exp. Cell Res., 210: 236-242, 1994.
25. Ha, K., and Exton, J. H. Differential translocation of protein kinase C isozymes by thrombin and platelet-derived growth factor a possible function for phosphatidylcholine-derived diacylglycerol. J. Biol. Chem., 268: 10534-10539, 1993.
26. Rusnak, J. M., and Lazo, J. S. Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Exp. Cell Res., 244: 189-199, 1996.
27. Mischak, H., Kolch, W., Goodnight, J., Davidson, W. F., Rapp, U., RoseJone, S., and Mushinski, J. F. Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. J. Immunol., 147; 3981-3987, 1991.
28. Cacace, A. M., Guadagno, S. N., Krauss, R. S., Fabbro, D., and Weinstein, I. B. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene, 8; 2095-3104, 1993.
29. Mischak, H., Goodnight, J., Kolch, W., Martiny-Baron, G., Schaechtle, C., Kazanietz, M. G., Blumberg, P. M., Pierce, J. H., and Mushinski, J. F. Overexpression of protein kinase C-δ and -∈ in NIH3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J. Biol. Chem., 268; 6090-6096, 1993.
30. Kiss, Z., and Anderson, W. H. Selective downregulation of protein kinase C-∈ by carcinogens does not prevent stimulation of phospholipase D by phorbol ester and platelet-derived growth factor. Biochem. J., 300: 751-756, 1994.
31. Ueffing, M., Lovric, J., Philipp, A., Mischak, H., and Kolch, W. Protein kinase C-∈ associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity. Oncogene, 15: 2921-2927, 1997.
32. Lehel, C., Olah, Z., Mischak, H., Mushinski, F. J., and Anderson, W. B. Overexpressed protein kinase C-δ and -∈ subtypes in NIH3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake. J. Biol. Chem., 269: 4761-4766, 1994.
33. Lehel, C., Olah, Z., Jakab, G., Szallasi, Z., Petrovics, G., Harta, G., Blumberg, P. M., and Anderson, W. B. Protein kinase C ∈ subcellular localization domains and proteolytic degradation sites. J. Biol. Chem., 270: 19651-19658, 1995.
34. Lehel, C., Olah, Z., Jakab, G., and Anderson, W. B. Protein kinase C ∈ is localized to the Golgi via its zinc-finger domain and modulates Golgi function. Proc. Natl. Acad. Sci. USA, 92: 1406-1410, 1995.
35. Mochly-Rosen, D. Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science (Washington DC), 268: 247-251, 1995.
36. Kronfeld, I., Zsukerman, A., Kazimirsky, G., and Brodie, C. Staurosporine induces astrocytic phenotypes and differential expression of specific PKC isoforms in C6 glial cells. J. Neurochem., 65: 1505-1514, 1995.
37. 2+-activated and phospholipid-dependent protein kinase. Proc. Natl. Acad. Sci. USA, 83; 8535-8539, 1986.
38. Ohno, S., Akita, Y., Konno, Y., Imajoh, S., and Suzuki, K. A novel phorbol ester receptor/protein kinase, nPKC, distantly related to the protein kinase C family. Cell, 53: 731-741, 1988.
39. Nakanishi, H., and Exton, J. H. Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. J. Biol. Chem., 267: 16347-16354, 1992.
40. Basu, A., and Lazo, J. S. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Cancer Res., 52: 3119-3124, 1992.
41. Hill, B. T., Whelan, R. D. H., Gibby, E. M., Sheer, E., Hosking, L. K., Shellard, S. A., and Rupniak, H. T. Establishment and characterization of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies. Int. J. Cancer, 39: 219-225, 1987.
42. Wolf, C. R., Hayward, I. P., Lawrie, S. S., Buckton, K., McIntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R., and Smyth, J. F. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int. J. Cancer, 39: 695-702, 1987.
43. Simmonds, A. P., and McDonald, E. C. Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay. Br. J. Cancer, 50: 317-326, 1984.
44. Barry, M. A., Behnke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins, and hyperthermia. Biochem. Pharmacol., 40: 2353-2362, 1990.
45. Iwata, M., Iseki, R., Sato, K., Tozawa, Y., and Ohoka, Y. Glucocorticoid-mediated apoptosis of thymocytes is associated with isozyme-specific translocation of protein kinase C. Int. Immunol. 6: 431-438, 1994.
46. Kim, C. Y., Giaccia, A. J., Strulovici, B., and Brown, J. M. Differential expression of protein kinase C ∈ protein in lung cancer cell lines by ionising radiation. Br. J. Cancer, 66: 844-849, 1992.
47. Basu, A., and Weixel, K. M. Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. Int. J. Cancer, 62: 457-460, 1995.
48. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990.
49. Ohmori, T., Morikage, T., Sugimoto, Y., Fujiwara, Y., Kasahara, K., Nishio, K., Ohta, S., Sasaki, Y., Takahashi, T., and Saijo, N. The mechanism of the difference in cellular uptake of platinum derivatives in nonsmall cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn. J. Cancer Res., 84: 83-92, 1993.
50. Spotts, G. D., and Hann, S. R. Enhanced translation and increased turnover of c-myc proteins occur during differentiation of murine erythroleukemia cells. Mol. Cell. Biol., 10: 3952-3964, 1990.
51. + absorption in rabbit cortical collecting duct. J. Clin. Invest., 95: 2749-2756, 1995.
52. Hong, W. S., Saijo, N., Sasaki, Y., Minato, K., Nakano, K., Nakagawa, K., Fujiwara, Y., Nomura, K., and Twentyman, P. R. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int. J. Cancer, 41: 462-467, 1988.
53. Zinkewich-Peotti, K., and Andrews, P. A. Loss of cis-diamminedi-chloro-platinum(II) resistance in human ovarian carcinoma cells selected for rhodamine-123 resistance. Cancer Res., 52: 1902-1907, 1992.